stockrow
Saturday 7 November 2026
Export SNDX’s income statement to Excel — free account
Syndax Pharmaceuticals, Inc.
SNDX Healthcare Biotechnology
Syndax Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $172.4 million, up 627.8% from fiscal 2024.
- Revenue
- +81.6%
- EPS
- +21.4%
- Free cash flow
- +61.4%
- Total debt
- +71.1%
Quarter to September 2026, against a year earlier
9.54
0.17
+1.81%
Follow SNDX
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
5.83 | 7.72 | 9.49 | 10.56 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(61.94) | (64.26) | (40.95) | (26.19) | |
P/B ratio |
0.00 | 128.84 | 49.53 | 28.16 | |
Price to Tangible BV |
0.00 | 128.84 | 49.53 | 28.16 | |
EV/Sales |
6.43 | 7.94 | 9.52 | 10.29 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(10.50) | (9.07) | (7.43) | (5.49) | |
EV/FCF |
(10.49) | (9.06) | (7.43) | (5.49) | |
Quick Ratio |
4.25 | 6.26 | 4.88 | 4.01 | |
Current Ratio |
4.69 | 6.77 | 5.47 | 4.40 | |
Net Debt/EBITDA |
(3.49) | (0.84) | 0.50 | 1.09 | |
Debt/Assets |
84.93% | 83.58% | 72.77% | 64.92% | |
Debt/Equity |
(34.24) | 38.95 | 8.26 | 5.32 | |
Asset Turnover |
0.47 | 0.39 | 0.39 | 0.27 | |
Operating CF/Net income |
0.55 | 0.61 | 1.18 | 1.02 | |
Capex/Depreciation |
0.00 | 0.08 | 0.00 | 0.04 | |
Interest Coverage |
(3.23) | (3.16) | (2.89) | (5.75) | |
Research and Development Expense of Revenue |
81.01% | 93.47% | 90.72% | 114.84% | |
Selling, General and Administrative Expense of Revenue |
52.48% | 57.07% | 57.95% | 72.91% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
18.35% | 19.25% | 18.58% | 16.43% | |
Graham Net Nets |
(0.08) | (0.01) | 0.02 | 0.03 | |
Graham Number |
3.19 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(12.56%) | (11.48%) | (11.94%) | (15.66%) | |
Free Cash Flow Yield |
(10.52%) | (11.35%) | (13.49%) | (17.74%) | |
Revenue per Share |
0.93 | 0.82 | 0.74 | 0.79 | |
Operating CF per Share |
(0.30) | (0.34) | (0.57) | (0.80) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.30) | (0.34) | (0.57) | (0.80) | |
Cash per Share |
4.87 | 6.23 | 4.09 | 4.78 | |
Shareholders Equity per Share |
(0.19) | 0.17 | 0.47 | 0.75 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.19) | 0.17 | 0.47 | 0.75 | |
Free Cash Flow |
(27.25) | (30.31) | (50.34) | (69.54) | |
Working Capital |
446.47 | 575.36 | 385.00 | 407.97 | |
Capital Expenditures |
0.00 | (0.04) | — | (0.06) | |
Net Current Asset Value |
(142.41) | (13.51) | 40.13 | 63.01 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
58.93 | 52.76 | 39.10 | 39.69 | |
Average Payables |
8.70 | 11.11 | 10.45 | 14.10 | |
Average Inventory |
32.19 | 25.43 | 19.81 | 16.56 | |
Average Assets |
622.23 | 649.90 | 556.69 | 627.26 | |
Average Common Equity |
49.13 | 86.26 | 128.34 | 176.38 |
Columns are period end dates · fundamentals updated 6 Nov 2026